• News and Events

    • Reuters: U.S. prescription drug spending to hit $400 billion a year by 2020: IMS


      U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by health care information company IMS Health Holdings Inc on Thursday.

    • Bloomberg: Prescription Drug Spending Hits Record $425 Billion in U.S.


      Spending on prescription drugs in the U.S. rose 12 percent to a record $425 billion before discounts last year, boosted in part by the introduction of breakthrough medicines for cancer and the growing number of patients seeking treatment for hepatitis C.

    • Wall Street Journal: U.S. Drug Spending Climbs


      Total spending on prescription drugs in the U.S. rose 12.2% to nearly $425 billion in 2015, continuing a steep climb fueled by the introduction in recent years of expensive new drugs for cancer and infections, as well as price hikes for older drugs, according to a new report.

    • Associated Press: Report: US medicine spending up 8.5 percent 2015


      A report from data firm IMS Health estimates patients, insurers, government programs and other payers spent a combined $309.5 billion last year on prescription medicines.

    • Forbes: Double-Digit Growth In Drug Spending Slows As Insurers Fight Back


      Thanks to rebates and other concessions awarded by pharma companies angling to get their new products onto insurance formularies, the net spending on drugs was $310 billion in 2015, growing only 8.5% from the previous year. And the average net price for existing brands rose just 2.8%—a significantly lower rate of growth than what was seen in previous years.

    • Healthcare BPO: IMS Health Shares Benefits and Trends of Outsourcing within the Healthcare Industry


      Software Magazine

      A recent study of the Global Healthcare Business Process Outsourcing (BPO) by Research and Markets, Global Healthcare BPO Market 2015 – 2019, indicates growth at a compound annual growth rate of 5.32 percent over the period of 2014 to 2019.

    • Which Way Now For Mid-Sized European Pharmas?


      Executive Summary

      Compared with their top 20 European peers and with similarly sized companies in the US, many mid-sized European pharmas are struggling. IMS Health analyzes the predicament these companies find themselves in and outlines what they need to do to avoid being caught in an evolutionary backwater.

    • 7 Stunning Findings Regarding Global Medicine Use by 2020


      The Motley Fool

      What does the future hold for global drug spending? According to the latest report from the IMS Institute for Healthcare Informatics, there are a number of surprising findings.

    • Identifying Switch Opportunities Worldwide


      OTCToolBox Innovations

      IMS Health's Andy Tisman is featured in this OTCToolBox Innovations article sharing key consumer health insights regarding the global trend of switching medicines from prescription to non-prescription status.

    • Cloud Marketing: Cloud Control



      To unlock the vast business potential of the cloud, pharma must first overcome its inherent resistance to change and then commit to tearing down those silo walls.

    • An Inside Look Into Developing an Apple Watch Platform



      IMS Health announced a new wearable app platform that is entirely dedicated to the life science industry. The platform, called IMSHealthWear 1.00, will also serve as the basis for two new apps: MGRWear and REPWear.

See More